Explore more publications!
Africa News Observer
Got News to Share?

Africa News Observer: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Observer.

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on November 7, 2025

T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 7, 2025

T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Indeterminate GlobeNewswire
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
November 7, 2025

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

Indeterminate GlobeNewswire
Trained Therapeutix Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 7, 2025

Trained Therapeutix Demonstrates RIDE-001 Trains Myeloid Cells for Anti-Tumor Immune Response in Preclinical Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Indeterminate GlobeNewswire
Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide
November 7, 2025

Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide

Indeterminate GlobeNewswire
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 7, 2025

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Indeterminate GlobeNewswire
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
November 7, 2025

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Indeterminate GlobeNewswire
Celldex to Present at Upcoming Investor Conferences
November 7, 2025

Celldex to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire
Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
November 7, 2025

Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025

Indeterminate GlobeNewswire
Vaxart to Host Upcoming Conference Calls
November 7, 2025

Vaxart to Host Upcoming Conference Calls

Indeterminate GlobeNewswire
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
November 7, 2025

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

Indeterminate GlobeNewswire
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
November 7, 2025

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025

Indeterminate GlobeNewswire
MAX Power Begins Historic Drilling of Canada’s First-Ever Natural Hydrogen Well
November 7, 2025

MAX Power Begins Historic Drilling of Canada’s First-Ever Natural Hydrogen Well

Indeterminate GlobeNewswire
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
November 7, 2025

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Indeterminate GlobeNewswire
TERRA CLEAN PROVIDES CORPORATE UPDATE
November 7, 2025

TERRA CLEAN PROVIDES CORPORATE UPDATE

Indeterminate GlobeNewswire
Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 7, 2025

Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Indeterminate GlobeNewswire
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
November 7, 2025

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Indeterminate GlobeNewswire
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
November 7, 2025

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

Indeterminate GlobeNewswire
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 7, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
MEXC Dominates Early-Stage Token Growth: AI, MEME, and DeFi Drive +1625% Performance Surge
November 7, 2025

MEXC Dominates Early-Stage Token Growth: AI, MEME, and DeFi Drive +1625% Performance Surge

Indeterminate GlobeNewswire
Research Update
November 7, 2025

Research Update

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions